Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

The promotion of olanzapine in primary care: an examination of internal industry documents.

Spielmans GI.

Soc Sci Med. 2009 Jul;69(1):14-20. doi: 10.1016/j.socscimed.2009.05.001.

PMID:
19481322
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
4.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
5.

Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.

Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG.

JAMA. 2011 Sep 28;306(12):1359-69. doi: 10.1001/jama.2011.1360. Review. Erratum in: JAMA. 2012 Jan 11;307(2):147.

PMID:
21954480
6.

Olanzapine: in adolescents with schizophrenia or bipolar I disorder.

McCormack PL.

CNS Drugs. 2010 May;24(5):443-52. doi: 10.2165/11204430-000000000-00000. Review.

PMID:
20369908
7.

[New formulations of olanzapine in the treatment of acute agitation].

Bartkó G.

Neuropsychopharmacol Hung. 2006 Dec;8(4):171-8. Review. Hungarian.

PMID:
17211052
8.

[Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].

Dilla T, Prieto L, Ciudad A, Sacristán JA.

Actas Esp Psiquiatr. 2004 Sep-Oct;32(5):269-79. Review. Spanish.

PMID:
15529211
9.

Olanzapine: a 5-year perspective.

Littrell KH, Petty RG, Wolf NM.

Expert Rev Neurother. 2006 Jun;6(6):811-21. Review.

PMID:
16784405
10.

Risperidone versus olanzapine for schizophrenia.

Jayaram MB, Hosalli P.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD005237. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD005237.

PMID:
15846745
11.

Use of olanzapine in the treatment of bipolar I disorder.

Lieberman DZ, Goodwin FK.

Expert Rev Neurother. 2004 Sep;4(5):759-67. Review.

PMID:
15853503
12.

Atypical antipsychotics for nursing home patients: a retrospective chart review.

Frenchman IB.

Drugs Aging. 2005;22(3):257-64. Review.

PMID:
15813657
13.

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].

McDonagh M, Peterson K, Carson S, Fu R, Thakurta S.

Portland (OR): Oregon Health & Science University; 2010 Jul.

14.

Olanzapine: a review of rapid and long-acting parenteral formulations.

Owen RT.

Drugs Today (Barc). 2010 Mar;46(3):173-81. doi: 10.1358/dot.2010.46.3.1476499. Review.

PMID:
20467591
15.

Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.

Hargreaves WA, Gibson PJ.

CNS Drugs. 2005;19(5):393-410. Review. Erratum in: CNS Drugs. 2005;19(9):784. Gibson, Joseph P [corrected to Gibson, P Joseph].

PMID:
15907151
16.

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.

Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, Riemsma R.

Health Technol Assess. 2004 May;8(19):iii-iv, 1-187. Review.

17.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
18.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients..

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

19.

Olanzapine for schizophrenia.

Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001359. Review.

PMID:
15846619
20.

Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Jan;63(1):140-50. doi: 10.1111/j.1742-1241.2008.01900.x. Review.

PMID:
18834452

Supplemental Content

Support Center